What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.”In the company’s words, NCT04243785 on ClinicalTrials.gov
- Tested for
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Advanced Solid Tumor, Metastatic Breast Cancer
- Main trialPhase 1
- “This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to 35 participants who are evaluable for toxicity. Once the MTD is determined, it is planned that an…”In the company’s words, NCT04243785 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Mar 2026 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | |
| Phase 1Recruiting | May 2026 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026